Gotowa bibliografia na temat „Triple negative breast cancers”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Triple negative breast cancers”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Triple negative breast cancers"
Ray, Mandira, i Blase N. Polite. "Triple-Negative Breast Cancers". Cancer Journal 16, nr 1 (styczeń 2010): 17–22. http://dx.doi.org/10.1097/ppo.0b013e3181d3eef5.
Pełny tekst źródłaGonzalez, Lorena, Joanne Mortimer i Laura Kruper. "De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer". Current Breast Cancer Reports 13, nr 3 (14.06.2021): 151–56. http://dx.doi.org/10.1007/s12609-021-00421-3.
Pełny tekst źródłaAnderson, Kristin, Patricia Thompson, Betsy Wertheim, Lorena Martin, Ian K. Komenaka, Melissa Bondy, Adrian Daneri-Navarro i in. "Family history and breast cancer subtype among women of Mexican descent." Journal of Clinical Oncology 32, nr 26_suppl (10.09.2014): 41. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.41.
Pełny tekst źródłaSTADALNYKAITĖ, Sigutė, i Rūta BRIEDIENĖ. "Radiological diagnostics of triple negative breast cancer: a review". Acta medica Lituanica 18, nr 2 (1.04.2011): 98–106. http://dx.doi.org/10.6001/actamedica.v18i2.1822.
Pełny tekst źródłaLu, Boya, Elango Natarajan, Hanumantha Rao Balaji Raghavendran i Uma Devi Markandan. "Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review". Technology in Cancer Research & Treatment 22 (styczeń 2023): 153303382211452. http://dx.doi.org/10.1177/15330338221145246.
Pełny tekst źródłaBhatti, Abu Bakar Hafeez, Amina Iqbal Khan, Neelam Siddiqui, Narjis Muzaffar i Mazhar Ali Shah. "Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conservative therapy." Journal of Clinical Oncology 31, nr 26_suppl (10.09.2013): 70. http://dx.doi.org/10.1200/jco.2013.31.26_suppl.70.
Pełny tekst źródłaKuo, Wen-Hung, Yao-Yin Chang, Ming-Feng Hou, Eric Y. Chuang i King-Jen Chang. "Molecular characteristics and metastasis predictor genes of triple-negative breast cancer." Journal of Clinical Oncology 30, nr 15_suppl (20.05.2012): 1043. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1043.
Pełny tekst źródłaChirappapha, Prakasit, Thongchai Sukarayothin, Yodying Wasuthit, Ronnarat Suvikapalornkul, Panuwat Lertsithichai i Youwanush Kongdan. "Disease-free Probability and Triple-Negative Breast Cancer". Ramathibodi Medical Journal 35, nr 1 (30.03.2012): 5–13. http://dx.doi.org/10.33165/rmj.2012.35.1.117663.
Pełny tekst źródłaZoghi, Behyar, i Peter Ravdin. "Improving the efficacy of chemotherapy drugs for the treatment of triple-negative breast cancers." Journal of Clinical Oncology 30, nr 27_suppl (20.09.2012): 107. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.107.
Pełny tekst źródłaAndre, F., P. Dessen, B. Job, S. Delaloge, L. Pusztai i V. Lazar. "Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer". Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): 569. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.569.
Pełny tekst źródłaRozprawy doktorskie na temat "Triple negative breast cancers"
Kravalis, Saulius [Verfasser], i Elmar [Akademischer Betreuer] Stickeler. "MicroRNA signatures in triple-negative breast cancer". Freiburg : Universität, 2016. http://d-nb.info/1139977482/34.
Pełny tekst źródłaPerera, Don Franciscuge Thilini N. "Targeting Focal Adhesion Kinase (FAK) in Triple Negative Breast Cancer (TNBC)". Thesis, Griffith University, 2020. http://hdl.handle.net/10072/397040.
Pełny tekst źródłaThesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Environment and Sc
Science, Environment, Engineering and Technology
Full Text
Basree, Mustafa M. "Implications of Breastfeeding in Triple Negative Breast Cancer". The Ohio State University, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=osu1492791260508232.
Pełny tekst źródłaAlbukhari, Ashwag. "Targeting EGFR signalling pathway in triple negative breast cancer". Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:85d4bb10-385e-4187-8576-cf04f15f2871.
Pełny tekst źródłaPipili, Aikaterini. "The role of IQGAP3 in triple negative breast cancer". Thesis, King's College London (University of London), 2017. https://kclpure.kcl.ac.uk/portal/en/theses/the-role-of-iqgap3-in-triple-negative-breast-cancer(bb661f8b-46f8-4917-9734-8285c3c60867).html.
Pełny tekst źródłaMohamad, Hanif Ezanee Azlina Binti. "The identification and characterisation of markers clinical outcome in triple negative breast cancers (TNBCs)". Thesis, Queen's University Belfast, 2017. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.728192.
Pełny tekst źródłaSadacca, Benjamin. "Pharmacogenomic and High-Throughput Data Analysis to Overcome Triple Negative Breast Cancers Drug Resistance". Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLS538/document.
Pełny tekst źródłaGiven the large number of treatment-resistant triple-negative breast cancers, it is essential to understand the mechanisms of resistance and to find new effective molecules. First, we analyze two large-scale pharmacogenomic datasets. We propose a novel classification based on transcriptomic profiles of cell lines, according to a biological network-driven gene selection process. Our molecular classification shows greater homogeneity in drug response than when cell lines are grouped according to their original tissue. It also helps identify similar patterns of treatment response. In a second analysis, we study a cohort of patients with triple-negative breast cancer who have resisted to neoadjuvant chemotherapy. We perform complete molecular analyzes based on RNAseq and WES. We observe a high molecular heterogeneity of tumors before and after treatment. Although we highlighted clonal evolution under treatment, no recurrent mechanism of resistance could be identified Our results strongly suggest that each tumor has a unique molecular profile and that that it is increasingly important to have large series of tumors. Finally, we are improving a method for testing the overrepresentation of known RNA binding protein motifs in a given set of regulated sequences. This tool uses an innovative approach to control the proportion of false positives that is not realized by the existing algorithm. We show the effectiveness of our approach using two different datasets
Kishi, Masae. "Strategies of Cancer Immunotherapy : Model of Triple Negative Breast Cancer". Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS070.
Pełny tekst źródłaCancer stem cells (CSCs) are responsible for tumor progression, metastases, and late relapses. They have been identified in many cancers, such as triple negative breast cancer (TNBC) and grade III to IV cancers. They are resistant to chemotherapy and radiotherapy and reside in an immuno-repressive niche.This study aims to evaluate a immunotherapy strategy that selectively targets CSCs in the mouse model 4T1-GFP-Luc mimicking TNBC. The phenotype / genotype of mammosphere was initially characterized. Based on genomic analysis of CSC, we have developed an active immunotherapy associated with immunomodulatory agents. We measured the size of tumors and monitored the appearance of metastases by bioluminescence. We performed an immunological study and genomic tumor analysis. The therapeutic combination causes the recruitment of CD4 + and CD8 + T lymphocytes and B lymphocytes with increased CXCL13, the reduction of T reg cells and suppressive myeloid cells in the tumor. This induction of intra-tumor immune response leads to a decrease in tumor size and metastases.This new active immunotherapy can be used in combination with current treatments for prophylactic and curative measures in a wide variety of cancers
Kishi, Masae. "Strategies of Cancer Immunotherapy : Model of Triple Negative Breast Cancer". Electronic Thesis or Diss., Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS070.
Pełny tekst źródłaCancer stem cells (CSCs) are responsible for tumor progression, metastases, and late relapses. They have been identified in many cancers, such as triple negative breast cancer (TNBC) and grade III to IV cancers. They are resistant to chemotherapy and radiotherapy and reside in an immuno-repressive niche.This study aims to evaluate a immunotherapy strategy that selectively targets CSCs in the mouse model 4T1-GFP-Luc mimicking TNBC. The phenotype / genotype of mammosphere was initially characterized. Based on genomic analysis of CSC, we have developed an active immunotherapy associated with immunomodulatory agents. We measured the size of tumors and monitored the appearance of metastases by bioluminescence. We performed an immunological study and genomic tumor analysis. The therapeutic combination causes the recruitment of CD4 + and CD8 + T lymphocytes and B lymphocytes with increased CXCL13, the reduction of T reg cells and suppressive myeloid cells in the tumor. This induction of intra-tumor immune response leads to a decrease in tumor size and metastases.This new active immunotherapy can be used in combination with current treatments for prophylactic and curative measures in a wide variety of cancers
Brancato, Jennifer M. "Defining the Mechanism of Action of Bromodomain and Extraterminal Inhibitors in Triple-Negative Breast Cancers". Case Western Reserve University School of Graduate Studies / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=case1522842642716411.
Pełny tekst źródłaKsiążki na temat "Triple negative breast cancers"
Tan, Antoinette R., red. Triple-Negative Breast Cancer. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-69980-6.
Pełny tekst źródłaU, Lin Nancy, red. 100 questions and answers about triple negative breast cancer. Sudbury, Mass: Jones and Bartlett Publishers, 2012.
Znajdź pełny tekst źródłaSurviving triple negative breast cancer: Hope, treatment, and recovery. Oxford: Oxford University Press, 2013.
Znajdź pełny tekst źródłaDeng, Xiyun, Faqing Tang i Thomas J. Rosol. Triple-Negative Breast Cancer. WORLD SCIENTIFIC, 2020. http://dx.doi.org/10.1142/11199.
Pełny tekst źródłaDeng, Xiyun, i Junjiang Fu. Triple-Negative Breast Cancer. World Scientific Publishing Co Pte Ltd, 2020.
Znajdź pełny tekst źródłaTan, Antoinette R. Triple-Negative Breast Cancer: A Clinician’s Guide. Springer, 2019.
Znajdź pełny tekst źródłaTan, Antoinette R. Triple-Negative Breast Cancer: A Clinician’s Guide. Springer, 2018.
Znajdź pełny tekst źródłaMir, Manzoor Ahmad. Combinational Therapy in Triple Negative Breast Cancer. Elsevier Science & Technology Books, 2022.
Znajdź pełny tekst źródłaMir, Manzoor Ahmad. Combinational Therapy in Triple Negative Breast Cancer. Elsevier Science & Technology, 2022.
Znajdź pełny tekst źródłaYarbro, Connie Henke. 100 Q and As about Triple Negative Breast. Jones & Bartlett Learning, LLC, 2019.
Znajdź pełny tekst źródłaCzęści książek na temat "Triple negative breast cancers"
Ismail-Khan, Roohi, Susan Minton i Nazanin Khakpour. "Triple-Negative Breast Cancer". W Breast Disease, 463–72. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1145-5_29.
Pełny tekst źródłaVohra, Poonam, Gregor Krings i Yunn-Yi Chen. "Less Common Triple Negative Breast Cancers". W A Comprehensive Guide to Core Needle Biopsies of the Breast, 445–518. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26291-8_12.
Pełny tekst źródłaVohra, Poonam, Yunn-Yi Chen i Gregor Krings. "Less Common Triple-Negative Breast Cancers". W A Comprehensive Guide to Core Needle Biopsies of the Breast, 463–573. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-05532-4_12.
Pełny tekst źródłaTelli, Melinda L. "Triple-Negative Breast Cancer". W Molecular Pathology of Breast Cancer, 71–80. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-41761-5_6.
Pełny tekst źródłaPaquette, Benoit. "Triple-Negative Breast Cancer". W Encyclopedia of Cancer, 1–3. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_5981-2.
Pełny tekst źródłaVankina, Ritika, i Yuan Yuan. "Triple-Negative Breast Cancer". W Oncology in the Precision Medicine Era, 209–23. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-31471-2_13.
Pełny tekst źródłaPaquette, Benoit. "Triple-Negative Breast Cancer". W Encyclopedia of Cancer, 4658–60. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_5981.
Pełny tekst źródłaAvery, Tiffany P. "Triple-Negative Breast Cancer". W Changing Paradigms in the Management of Breast Cancer, 155–66. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-60336-0_11.
Pełny tekst źródłaLivasy, Chad A. "Pathologic Evaluation of Triple-Negative Breast Cancer". W Triple-Negative Breast Cancer, 1–22. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-69980-6_1.
Pełny tekst źródłaDuma, Narjust, Ciara C. O’Sullivan, Kathryn J. Ruddy i Alexis D. Leal. "Special Issues in Young Women with Triple-Negative Breast Cancer". W Triple-Negative Breast Cancer, 141–58. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-69980-6_10.
Pełny tekst źródłaStreszczenia konferencji na temat "Triple negative breast cancers"
Kern, P., i M. Rezai. "Abstract P2-10-14: Triple Negative Breast Cancer: prognosis of triple-negative breast cancers and non-triple-negative breast cancers in a large registry of certified breast units". W Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p2-10-14.
Pełny tekst źródłaSundqvist, M., L. De Koning, G. Rigaill, T. Dubois i J. Chiquet. "PO-435 Proteomic classification of triple negative breast cancers". W Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.946.
Pełny tekst źródłaSouza, Fabiana Lúcia de Lima, Francielle Souza Silva Lopes, Hellen Karine Paes Porto i Cesar Augusto Sam Tiago Vilanova Costa. "TRIPLE-NEGATIVE BREAST CANCER AND BRCA1 UNDEREXPRESSION ASSOCIATION: AN EVIDENCEBASED META-ANALYSIS OF CASE–CONTROL STUDIES". W Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2010.
Pełny tekst źródłaYuan, Hebao, Hongwei Guo, Feng Li, Joseph Burnett, Miao He, Nathan Truchan, Ila Myers i Duxin Sun. "Abstract 4788: Abraxane eliminates cancer stem cells in triple-negative breast cancers". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4788.
Pełny tekst źródłaRoesler, Alexander S., Smriti Malasi, Elizabeth Lenkiewicz, Barbara A. Pockaj, Michael T. Lewis, Lacey E. Dobrolecki, Lori Koslosky, Peter Hartmayer, Karen S. Anderson i Michael T. Barrett. "Abstract 1790: PDJ amplicon heterogeneity in triple negative breast cancers". W Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-1790.
Pełny tekst źródłaErson-Bensan, Ayse Elif, Begum H. Akman, Merve Oyken, Hizlan H. Agus, Esra Yavuz, Murat Erdem i Tolga Can. "Abstract 3374: APA isoform diversity in triple negative breast cancers". W Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3374.
Pełny tekst źródłaElsberger, B., SM Tovey, BA Tan, SB Brown, VG Brunton, EA Mallon, TG Cooke i J. Edwards. "Phosphorylated c-Src predicts clinical outcome in triple negative breast cancers." W CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-2076.
Pełny tekst źródłaKurata, K., M. Kubo, H. Mori, H. Kawaji, Y. Motoyama, L. Kuroki, M. Yamada, K. Kaneshiro, M. Kai i M. Nakamura. "Abstract P1-06-11: Microsatellite instability in triple negative breast cancers". W Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p1-06-11.
Pełny tekst źródłaAnwar, Talha, Heather Moore, Sarah Bergholtz i Celina Kleer. "Abstract 4790: Noncanonical functions of EZH2 in triple-negative breast cancers". W Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4790.
Pełny tekst źródłaAgner, Shannon C., Jun Xu, Hussain Fatakdawala, Shridar Ganesan, Anant Madabhushi, Sarah Englander, Mark Rosen i in. "Segmentation and classification of triple negative breast cancers using DCE-MRI". W 2009 IEEE International Symposium on Biomedical Imaging: From Nano to Macro (ISBI). IEEE, 2009. http://dx.doi.org/10.1109/isbi.2009.5193283.
Pełny tekst źródłaRaporty organizacyjne na temat "Triple negative breast cancers"
Qi, Chao. PPAR Delta as a Therapeutic Target in Triple-Negative Breast Cancers. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2012. http://dx.doi.org/10.21236/ada568147.
Pełny tekst źródłaQi, Chao. PPAR Delta as a Therapeutic Target in Triple-negative Breast Cancers. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2011. http://dx.doi.org/10.21236/ada560836.
Pełny tekst źródłaYee, Amy S. Triple Negative Breast Cancer and Metabolic Regulation. Fort Belvoir, VA: Defense Technical Information Center, sierpień 2014. http://dx.doi.org/10.21236/ada612056.
Pełny tekst źródłaGonzalez-Perez, Ruben R. Targeting Breast Cancer Stem Cells In Triple Negative Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, październik 2014. http://dx.doi.org/10.21236/ada613188.
Pełny tekst źródłaGautier, Jean. Evaluating Interstrand Crosslink (ICL) Repair in Triple-Negative Breast Cancers to Guide Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, kwiecień 2012. http://dx.doi.org/10.21236/ada586664.
Pełny tekst źródłaRicher, Jennifer K. Reversing Anoikis Resistance in Triple-Negative Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, październik 2014. http://dx.doi.org/10.21236/ada613479.
Pełny tekst źródłaCecil, Denise. Development of a Vaccine Targeting Triple-Negative Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2012. http://dx.doi.org/10.21236/ada567745.
Pełny tekst źródłaRussell, Tanya. Does Lactation Mitigate Triple Negative/Basal Breast Cancer Progression? Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2012. http://dx.doi.org/10.21236/ada580133.
Pełny tekst źródłaCecil, Denise. Development of a Vaccine Targeting Triple-Negative Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, listopad 2013. http://dx.doi.org/10.21236/ada592218.
Pełny tekst źródłaRussell, Tanya. Does Lactation Mitigate Triple Negative/Basal Breast Cancer Progression. Fort Belvoir, VA: Defense Technical Information Center, listopad 2013. http://dx.doi.org/10.21236/ada594430.
Pełny tekst źródła